Product Information
NIKKI 3 MG-0.02 MG TABLET is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.1909 per EA under NDC 68180088673. Its NADAC has been published 348 times since Feb 5, 2020.
FDA first approved this application on May 27, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180088673
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA201661FDA Approved
5/27/2014
TE Code
AB
On Market Since
11/30/2019
Price Statistics
The NADAC for NIKKI 3 MG-0.02 MG TABLET has been published 348 times since Feb 5, 2020, and over the history we have for it it has declined 55.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1909 per EA |
|---|---|
| All-time high | $0.4650 (Sep 16, 2020) |
| All-time low | $0.1278 (Nov 20, 2024) |
| 52-week high | $0.1933 |
| 52-week low | $0.1538 |
| Median price | $0.2731 |
| Average price | $0.2775 |
| Largest weekly change | -32.1% (Nov 20, 2024) |
| Weeks tracked | 348 |
| Tracking since | Feb 5, 2020 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 22% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
drospirenone and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NIKKI 3 MG-0.02 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NIKKI 3 MG-0.02 MG TABLET, manufactured by Lupin Pharmaceuticals Inc., is $0.1909 per EA (NDC 68180088673), effective Sep 30, 2026.
How has the price of NIKKI 3 MG-0.02 MG TABLET changed over time?
Over the history we have for it, the NADAC for NIKKI 3 MG-0.02 MG TABLET has declined 55.5%. It has been tracked across 348 weekly CMS publications since Feb 5, 2020.
What are the highest and lowest recorded NADAC prices for NIKKI 3 MG-0.02 MG TABLET?
Since Feb 5, 2020, the NADAC for NIKKI 3 MG-0.02 MG TABLET has ranged from a low of $0.1278 (Nov 20, 2024) to a high of $0.4650 (Sep 16, 2020), with a median of $0.2731 per EA.
Are there cheaper alternatives to NIKKI 3 MG-0.02 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DROSPIRENONE-EE 3-0.03 MG TAB, is $0.1492 per EA — about 22% below NIKKI 3 MG-0.02 MG TABLET.
Who manufactures NIKKI 3 MG-0.02 MG TABLET?
NIKKI 3 MG-0.02 MG TABLET (NDC 68180088673) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.